Beximco Pharma’s blood pressue drug approved by US FDA

Beximco Pharmaceuticals Limited has set the record of being the first Bangladeshi pharmaceutical company receiving blood pressure drug manufacturing and export approval by US FDA.  A comprehensive research and review of the submitted dossier and the manufacturing process of the company was undertaken by the US Food and Drug Administration (US FDA) for granting the formal approval. Beximco has been approved to manufacture ‘Carvedilol’, a common drug for blood pressure. The company can manufacture this drug in different strengths at its Tongi plant which has been recently appoved by the US regulatory authority.

It is for the first time that the US FDA has approved a medicine to be manufactured in Bangladesh for supply into the US market. This is yet another benchmark of success and excellence established by the company in the Pharmaceutical industry.

Managing Director of Beximco Pharma Nazmul Hassan said: “We are increasingly focused on building our presence in the US generics market, and this approval marks the beginning of a new era for the Bangladesh pharmaceutical industry.”

The export of Carvedilol is expected to commence in the first half of the year 2016. A full-year export revenue of $3-$4 million is expected to be generated from this product by the company.

Beximco Pharmaceuticals limited is emerging as one of the leading exporter of medicines in the country with its services and facilities well recognized by the regulatory authorities of various countries like USA, European Union, Australia, Canada, and Brazil etc.